Representative Experience

• Havencrest Capital Management Acquires Tekton

  We represented Havencrest Capital Management, a Dallas-based, private equity fund manager specializing in the healthcare industry, in its acquisition of Tekton, a clinical trial site network with 23 sites across Texas, Colorado, Georgia, Kansas, and Oklahoma. Terms of the transaction were not disclosed.

• Counseling on AI Development and Validation

  We advised hospitals, research institutions, life sciences companies, and Institutional Review Boards on the collection, use, and sharing of data and specimens for AI development and validation.

• Counsel for PathAI

  We represent PathAI, an AI-powered pathology company, across a variety of matters, including advising on mergers and acquisitions, healthcare and research policies and agreements, and laboratory compliance.

• Northlane Capital Partner Acquires SAI MedPartners

  Representation of Northlane Capital Partners, a middle market private equity firm, in its acquisition of SAI MedPartners, a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. Terms of the transaction were not disclosed.

• Complete Health Partners Acquires Simon-Williamson Clinic

  Representation of Complete Health Partners, a Pharos Capital portfolio company and a physician-driven, technology-enabled primary care practice, in its acquisition of Simon-Williamson Clinic, a medical group practice with four locations. Terms of the transaction were not disclosed.

• Assisted University with Federal Grants Compliance and International Projects

  Advise a public university system on compliance with the rules associated with grants and contracts from NIH, NSF, and the Department of Defense

• Lead Counsel to POINT Biopharma Inc. in its SPAC Business Combination with Research Alliance Corp. I

  Lead Counsel to POINT Biopharma Inc. in connection with its proposed SPAC business combination with Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I (Nasdaq: RACA), a special purpose acquisition company, sponsored by RA Capital Management.  Upon closing, the combined company will be named POINT Biopharma Global Inc. and is expected to be listed on Nasdaq under the ticker symbol “PNT”.

• Assisted Boston Children’s Hospital with VaccineFinder

  Represented Boston Children’s Hospital with intellectual property, business, and government contracting issues associated with VaccineFinder

• Assisted Children’s Hospital with Research Agreements

  Assisted a prominent children’s hospital with a range of industry-sponsored and investigator-initiated research agreements

• Counseled Research University on Multi-National Investigator-Initiated Clinical Trial

  Counseled a major research university with all regulatory and contracting aspects of a multi-national investigator-initiated clinical trial

Additional Experience